Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
This study has been completed.
Sponsor:
QRxPharma Inc.
Information provided by (Responsible Party):
QRxPharma Inc.
ClinicalTrials.gov Identifier:
NCT00818493
First received: January 6, 2009
Last updated: May 15, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain |
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride) Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride) Drug: Percocet (oxycodone and acetaminophen) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty |
Resource links provided by NLM:
MedlinePlus related topics:
Knee Replacement
Drug Information available for:
Morphine sulfate
Oxycodone
Acetaminophen
Oxycodone hydrochloride
Sulfate ion
U.S. FDA Resources
Further study details as provided by QRxPharma Inc.:
Primary Outcome Measures:
- Difference in pain intensity scores from baseline [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Safety: adverse events [ Time Frame: Throughout the 48 hour period ] [ Designated as safety issue: Yes ]
| Enrollment: | 44 |
| Study Start Date: | February 2009 |
| Study Completion Date: | July 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Q8003, flexible ascending dose
|
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)
IR Capsules, ascending flexible dose, every 4 to 6 hours
|
|
Experimental: 2
Low dose Q8003
|
Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
|
|
Active Comparator: 3
Percocet (oxycodone and acetaminophen)
|
Drug: Percocet (oxycodone and acetaminophen)
One or two 5mg/325 mg tablets every 4 to 6 hours
|
Detailed Description:
This Phase 2 study is a 3 arm, open-label pilot study to evaluate:
- the analgesic efficacy of a flexible ascending regimen of Q8003 compared to a low dose regimen of Q8003 (3 mg/2 mg and potentially up to 6 mg/ 4mg) and to 1-2 Percocet® 5 mg/325 mg tablets. Study drug will be administered every 4-6 hours over a 48-hour Treatment Period to inpatients with moderate to severe postoperative pain who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
- for the flexible ascending regimen of Q8003 treatment group, to evaluate the adequacy of the algorithm for conversion of IV PCA morphine to oral morphine equivalent doses of Q8003.
- the safety of the flexible ascending regimen of Q8003 administered over a 48-hour Treatment Period.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male of female, at least 18 years of age at time of enrollment.
- If female, be at least one year post-menopausal, surgically sterile or practicing effective contraception, be non-lactating, and if of child-bearing potential, have a negative urine pregnancy test result.
- Have a body mass index (BMI) of 38 kg/m2 or less.
- Have undergone a primary unilateral total knee arthroplasty or total hip arthroplasty performed under standardized general, spinal or epidural anesthesia.
- Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on the morning after surgery).
Exclusion Criteria:
- In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
- Used opiates continuously (including tramadol) for more than ten days in the past year.
- Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
- Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
- Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
- Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
- Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
- History of abusing licit or illicit drug substances within five (5) years of study entry.
- Has taken drugs known to interact with morphine or oxycodone metabolism, including, but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI), amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00818493
Locations
| United States, Alabama | |
| West Alabama Research, Inc. | |
| Birmingham, Alabama, United States, 35209 | |
| United States, Arizona | |
| Arizona Research Center | |
| Phoenix, Arizona, United States, 85023 | |
| United States, Michigan | |
| William Beaumont Hospital | |
| Royal Oak, Michigan, United States, 48073 | |
| United States, Texas | |
| Research Concepts, Ltd. | |
| Houston, Texas, United States, 77024 | |
Sponsors and Collaborators
QRxPharma Inc.
Investigators
| Study Director: | Patricia T. Richards, MD, Ph.D. | QRxPharma Inc. |
More Information
No publications provided
| Responsible Party: | QRxPharma Inc. |
| ClinicalTrials.gov Identifier: | NCT00818493 History of Changes |
| Other Study ID Numbers: | Q8003-020 |
| Study First Received: | January 6, 2009 |
| Last Updated: | May 15, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by QRxPharma Inc.:
|
total knee arthroplasty total hip arthroplasty |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Acetaminophen Acetaminophen, hydrocodone drug combination Morphine Oxycodone Antipyretics Physiological Effects of Drugs Pharmacologic Actions |
Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Analgesics, Opioid Central Nervous System Depressants Narcotics Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on May 16, 2013